

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 9.6 Indexed in PubMed

Marine Drugs



mdpi.com/ journal/ marinedrugs



Message from the Editor-in-Chief

The marine environment has become a recognized source for the discovery of bioactive compounds, as testified by the solid preclinical/clinical pipeline that currently exists for marine-derived products. *Marine Drugs* is inviting contributions on new advances in marine natural product chemistry, marine biotechnology, marine pharmacology and genomics related to the discovery of biologically and therapeutically relevant marine natural products. Our goal is to share sound contributions in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Associate Editors

Prof. Dr. Anake Kijjoa Prof. Dr. Vassilios Roussis Prof. Dr. Claudiu T. Supuran Dr. Hitoshi Sashiwa Prof. Dr. Marialuisa Menna Dr. Ipek Kurtboke Prof. Dr. Marc Diederich Prof. Dr. Yue-Wei Guo

Aims

Marine Drugs (ISSN 1660-3397) publishes peer-reviewed research papers, short notes, and reviews reporting on the discovery, development, exploitation, and production of biologically and therapeutically active compounds from marine habitats.

Scope

- Identification of bioactive compounds from marine microorganisms, invertebrates, fishes, and plants;
- Pharmacological characterization of marine compounds or their derivatives
- Marine natural products with activity against human, animal and plant diseases
- Marine natural products with insecticidal or herbicidal activities
- Synthesis, mutasynthesis and medicinal chemistry of marine natural products
- Marine proteomics, glycomics, and lipidomics related to drug discovery or bioactivity
- Marine drug development, including pharmaceutical formulation and clinical trials
- Marine chemical ecology research inspiring marine drug discovery
- Innovative sampling and isolation techniques targeting bioactive marine natural products
- Marine biotechnology and molecular biology studies; related to drug discovery or production
- Structural and biological characterization of marine toxins
- Biomaterials of marine origin
- Marine-derived ingredients for cosmeceuticals, nutraceuticals, marinederived functional foods and nutritional supplements

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

2023 Impact Factor 4.9

(Journal Citation Reports - Clarivate, 2024)

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures, or use of colors

Journal Rank

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Coverage by Leading Indexing Services

Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases

Rapid Publication

A first decision is provided to authors approximately 13.7 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the second half of 2024) MDPI is a member of



Affiliated Society:

Australia New Zealand Marine Biotechnology Society (ANZMBS)



Editorial Office marinedrugs@mdpi.com

MDPI Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 mdpi.com

January 2025

